Volume 20 - Issue 10 - October, 2008

Late Presentation of an Anomalous Origin of the Left Coronary Artery from the Pulmonary Artery: Case Report and Review

ABSTRACT: Anomalous origin of the left coronary artery (LCA) from the pulmonary artery (ALCAPA) is a rare cause of ischemia, heart failure and/or sudden death. A premortem diagnosis beyond early childhood is exceedingly rare because over 90% of untreated infants die in the first 12 months of life. We present a case of an asymptomatic fourteen-year old male with ALCAPA diagnosed by multidetector computed tomography (MDCT) angiography, who was successfully treated by surgical coronary transfer of the ALCAPA with reimplantation of the LCA to the aortic root.

J



Editor’s Message

Dear Readers,

This issue of the Journal of Invasive Cardiology continues our series of special focus sections to provide a more in-depth examination of important topics in cardiovascular medicine. The special section for the October 2008 issue includes articles focusing on the use of radial artery access for diagnostic and interventional catheterization procedures. The guest editor for this section is Dr. Deepak Bhatt, Chief of Cardiology at the VA Boston Healthcare system and director of the Integrated Interventional Cardiology Program at the VA and the Brigham and Women&rsquo



Three Cases of Left Main Stem Thrombus Complicating PCI: The Role of FilterWire Protection for the Virgin Territory

Author Affiliations:

Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University Hong Kong.

There are no grants, financial support, or conflicts of interests related to the research in this paper.

Manuscript submitted February 14, 2008, provisional acceptance given April 28, 2008, manuscript accepted June 3, 2008.

Address for correspondence: Eugene Brian Wu, MRCP, MD, Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University Hong Kong, Ngan Shing Street, Shatin, Hong Ko



Percutaneous Mitral Valvuloplasty through a Carpentier-Edwards Ring

Author Affiliations:

From the *Department of Cardiology A, University Hospital Ibn Sina, Rabat, Morocco, and the §Department of Cardiology B, University Hospital Ibn Sina, Rabat, Morocco.

The authors report no conflicts of interest regarding the content herein.

Manuscript submitted February 5, 2008, provisional acceptance given February 20, 2008, manuscript accepted March 3, 2008.

Address for correspondence: Belghiti Hasnaa, MD, Department of Cardiology B, University Hospital Ibn Sina, Rabat, Morocco. E-mail: [email protected]



Covered Stent for the Treatment of Recurrent Bilateral Renal Artery In-Stent Restenosis

Author Affiliations:

From the Cardiology Division, Section of Vascular Medicine, Massachusetts General Hospital and §Harvard Medical School, Boston, Massachusetts.

Disclosures: Dr. Rosenfield has received research grants from Idev, Abbott Vascular, Cordis Corp., Boston Scientific Corp., Bard, Baxter, Invatec, and Lumen; is a consultant to Cordis, Boston Scientific, Baxter, CardioMind, Micelle, Complete Conference Management, Idev, Abbott Vascular, Boston Biomedical Associates; owns stock in Lumen, CardioMind, Xtent, and Cardiomems; and has a financial relationship with VIVA



Late Outcomes after Drug-Eluting Stent Implantation in “Real-World” Clinical Practice

ABSTRACT: Background. We report the late outcomes in 411 consecutive patients undergoing drug-eluting stent (DES) implantation by a single operator between 2003–2006. Methods. Prospective registry with continuous follow up. Patients with stable angina (SA) or acute coronary syndrome (ACS) received DES for long lesions, small vessels, chronic total occlusion, bifurcation, aorto-ostial, left main, post atherectomy or saphenous vein graft lesions, multivessel/multilesion single vessel (V) disease, in-stent restenosis (ISR) or diabetes. Results. Age range: 34–86 yea



Percutaneous Repair of a Pseudoaneurysm Associated with Coarctation of the Aorta

Author Affiliations:

From the Department of Cardiology, Lahey Clinic Medical Center, Tufts University School of Medicine, Burlington, Massachusetts.

Disclosure: Dr. Piemonte is a member of the speaker’s bureau for Boston Scientific Corporation.

Manuscript submitted March 10, 2008, provisional acceptance given June 3, 2008, manuscript accepted June 11, 2008.

Address for correspondence: Wael F. Al-Husami, MD, Department of Cardiology, Lahey Clinic Medical Center, Tufts University School of Medicine, 41 Mall Road, Burlington, MA 01805. E-mail: [email protected]



Outcomes of DES in Real World Practice: Realizing the Potential

Since the approval of the drug-eluting stents (DES) in April of 2003 by the U.S. Food and Drug Administration (FDA) and a year earlier in Europe, the rise of DES had been phenomenal, a feat rarely seen in contemporary medicine. With much lower in-stent restenosis compared to their bare metal counterparts, use of DES in interventional cardiology immediately become the default choice in the cardiac catheterization laboratory. The randomized trials that led to the approval of both initial DES [sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES)] were applicable to a highly selec